GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.
- Conditions
- Hypertension
- First Posted Date
- 2007-11-02
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT00552708
- Locations
- πΊπΈ
GSK Investigational Site, Tacoma, Washington, United States
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
- Conditions
- Infections, Papillomavirus
- Interventions
- Biological: Cervarix TM
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2018-06-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 805
- Registration Number
- NCT00552279
- Locations
- πΈπ°
GSK Investigational Site, Trencin, Slovakia
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00551564
- Locations
- πΊπΈ
GSK Investigational Site, Chula Vista, California, United States
Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.
- Conditions
- Gastroesophageal Reflux DiseaseReflux, Gastroesophageal
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00551473
- Locations
- π¦πΊ
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia
A Second Study to Determine the Effect of GSK256073A on HVTs
- Conditions
- Healthy SubjectsDyslipidaemias
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT00551694
- Locations
- πΊπΈ
GSK Investigational Site, Minneapolis, Minnesota, United States
A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2008-12-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT00551772
- Locations
- πΊπΈ
GSK Investigational Site, Evansville, Indiana, United States
Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT00551811
- Locations
- π©πͺ
GSK Investigational Site, Berlin, Germany
A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men
- Conditions
- Atherosclerosis
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00551317
- Locations
- πΊπΈ
GSK Investigational Site, Honolulu, Hawaii, United States
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 331
- Registration Number
- NCT00550420
- Locations
- π¬π§
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom
An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 215
- Registration Number
- NCT00550407
- Locations
- π―π΅
GSK Investigational Site, Yamagata, Japan